Novel Method of Treating Macular Degeneration Using Botulinum Toxin-Based Pharmaceuticals

A method of treating or retarding progression of diabetic retinopathy in a patient, the method comprising:

• identifying a patient with diabetic retinopathy, with or without macular edema, but with severe microvascular dropout;
• administering an intravitreal anti-VEGF agent to the patient;
• and
• administering a botulinum neurotoxin or a fragment thereof to the patient in a periorbital or a para orbital region of the patient in a conventional dose, but not into an intra-ocular or a subconjunctival region of the patient.

A method of treating or retarding progression of uveitis with or without macular edema in a patient, the method comprising:

• Identifying a patient with edema or severe non-edematous changes;
• Administering an intravitreal anti-VEGF agent to the patient;
• and
• Administering a botulinum neurotoxin or a fragment thereof to the patient in a periorbital or a para orbital region of the patient in a conventional dose, but not into an intra-ocular or a subconjunctival region of the patient.